Thomas Zeltner

Last updated


Thomas Zeltner
Born (1947-11-15) November 15, 1947 (age 73)
NationalitySwiss
OccupationChairman WHO Foundation, physician, lawyer, and former Secretary of Health of Switzerland
Known forChairman WHO Foundation; Former Secretary of Health of Switzerland; co-founder of the Global Patient Safety Forum; Professor of Public Health at the University of Berne, Switzerland; Visiting Scientist at the Harvard School of Public Health; President of the Swiss Commission for UNESCO; and Board Member of the Medical University of Vienna

Thomas Zeltner (born 1947 in Berne, Switzerland) is a Swiss physician, lawyer, and current Chairman and interim CEO of the WHO Foundation. [1] He was also the former Secretary of Health of Switzerland Federal Department of Home Affairs FDHA. He has a long history in public health and has repeatedly been ranked among the 12 most influential political figures of Switzerland. [2]

Contents

Zeltner is Professor at the University of Berne, Switzerland, in Public Health and Visiting Scientist at the Harvard School of Public Health. He chairs the Swiss Research Institute for Public Health and Addiction (Zürich) and is President of UNESCO Commission of Switzerland. He advises the Swiss government in the implementation and future development of The National Health Policy. He is also the Vice Chair of the University Council of the Medical University of Vienna.

Past

Zeltner graduated with an M.D. and an LL.M. (master's in law) from the University of Berne. He specialized in human pathology and forensic medicine before becoming the head of Medical Services at the Bern University Hospital. He held various faculty positions at the University of Bern and at the Harvard School of Public Health. He is Doctor of law (honoris causa) of the University of Neuchâtel, Switzerland.

In 1991, the Swiss Government appointed Zeltner as the 8th Director-General of the Swiss National Health Authority and Secretary of Health of Switzerland, a position he held until the end of 2009.

Under Zeltner's leadership, Switzerland developed in 1991 a pioneering illicit drug policy, which has received global attention. It is based on a 4-pillar strategy (prevention, harm reduction, therapy, and law enforcement), which is enshrined in the Swiss law on narcotic drugs. The harm reduction policy of Switzerland – which includes large-scale syringe exchange programs (also in prisons) [3] and the medical prescription of heroin for chronic heroin addicts – was introduced against the strong opposition of the UN drug control authorities, [4] but endorsed by a majority of the Swiss population in several popular referenda. [5]

In 1999-2000, at the request of the then-Director General of WHO, Gro Harlem Brundtland, Zeltner chaired a committee which investigated the efforts of multinational tobacco companies to undermine tobacco control activities of the World Health Organization (2000). [6] This landmark report marks the beginning of the development of the WHO Framework Convention on Tobacco Control (2003). [7] With his efforts to reduce tobacco consumption in Switzerland, Zeltner became a favorite adversary of big tobacco and was nicknamed “the Tobacco Taliban." [8]

As director of the Swiss Federal Office of Public Health, he presided over changes to transform the regulated market model of the Swiss health care sector into a more value- and consumer-driven health care system. The Swiss model guarantees access to affordable insurance to all, even if they have pre-existing medical problems. All residents are required to buy insurance even if they are currently healthy, so that the risk pool remains reasonably favorable. Finally subsidies are given to low income families to pay for their premiums. Even though the Swiss pay 12.18% of the GDP for health (data 2018), [9] a majority of 78% considers that the system works well or very well. [10] The Swiss health care model is gaining increased international interest, particularly in the U.S. [11]

Zeltner was a member and Vice-President of the Executive Board of the World Health Organization (WHO) (1999-2002). He chaired the committee to reform the governance rules of the WHO in 2002-4. He was also Executive President of the WHO Regional Committee for Europe (1994–95) and Chairman of the Governing Council of the International Agency for Research on Cancer, (1998-2000). Between 2012 and 2014, Zeltner served the World Health Organization (WHO) in the capacity of a Special Envoy. [12] In this function he advised the Director General of WHO, Margaret Chan, in critical areas of the ongoing reform of this UN agency. [13] [14] The work was successfully completed by adoption of the Framework of Engagement with Non-State Actors (FENSA) by the World Health Assembly in May 2016.

Current position

In 2020, the World Health Organization (WHO) announced [15] that Zeltner was one of the founding board members and the first chairman of the WHO Foundation. As of May 2020, Zeltner is acting as interim CEO of the WHO Foundation. [16] The WHO Foundation is an independent grant-making foundation focused on addressing the most pressing global health challenges of today and tomorrow. [17]

He is co-founder of the Global Patient Safety Forum, a convening organization of world patient safety organizations; and a member of the steering board of the Global Patient Safety Challenge, Medication Safety, of the World Health Organization. He is a member of the editorial board of the journal Health Systems and Reform.

Since 1992, he has been Professor of Public Health at the University of Berne and is a Visiting Scientist at the Harvard School of Public Health (Boston). From 2018-22 he serves as a member of the Board of the Medical University of Vienna (Austria). Zeltner has served as Chairman of the board of the health insurer KPT until 2020, the leading online insurance company in Switzerland, which is repeatedly qualified as the best health insurer of Switzerland. [18] He is also president of Blood Transfusion CRS Switzerland, the organization in charge of securing Switzerland's provision with blood and blood products.

Related Research Articles

Prohibition of drugs Overview of the prohibition of drugs

The prohibition of drugs through sumptuary legislation or religious law is a common means of attempting to prevent the recreational use of certain intoxicating substances.

Harm reduction

Harm reduction, or harm minimization, refers to a range of public health policies designed to lessen the negative social and/or physical consequences associated with various human behaviors, both legal and illegal. Harm reduction policies are used to manage behaviors such as recreational drug use and sexual activity in numerous settings that range from services through to geographical regions.

Drug Policy Alliance American non-profit advocacy-organization

The Drug Policy Alliance (DPA) is a New York City–based non-profit organization that seeks to advance policies that “reduce the harms of both drug use and drug prohibition, and to promote the sovereignty of individuals over their minds and bodies” The organization prioritizes reducing the role of criminalization in drug policy, advocating for the legal regulation of marijuana, and promoting health-centered drug policies. DPA has been led by executive director Kassandra Frederique since September 2020.

Julio Frenk Mexican physician and politician

Julio José Frenk Mora (born December 20, 1953 is a Mexican physician and former government official who has been the president of the University of Miami since 2015. He is the University of Miami's first Hispanic and native Spanish-speaking president. Frenk formerly was Secretary of Health of Mexico from 2000 to 2006 and as dean of the faculty and T & G Angelopoulos professor of public health and international development at the Harvard School of Public Health, from 2009 to 2015, where he was the university's first Hispanic and native Spanish-speaking dean.

Drug policy reform, also known as drug law reform, generally refers to proposed changes to the laws and regulations that governments promulgate with respect to substances that have psychoactive effects or a real or perceived potential to be used for recreational or other non-medical reasons. Proponents of drug policy reform frequently argue that prohibition of recreational drugs—such as cannabis, opioids, cocaine, amphetamines and hallucinogens—has been ineffective and counterproductive and that substance use is better responded to by implementing practices for harm reduction and increasing the availability of addiction treatment. Another reform proposed is to introduce a regulatory regime for the production, marketing, and distribution of some or all currently illegal drugs in a manner analogous to that for alcohol and tobacco.

Action on Smoking and Health (ASH) is the name of a number of autonomous pressure groups (charities) that seek to publicize the risks associated with tobacco smoking and campaign for greater restrictions on cigarette and tobacco sales.

Anti-Narcotics Force Federal executive bureau of Pakistan

The Anti-Narcotics Force is a Federal Executive bureau of the Government of Pakistan, tasked with combating the narcotics smuggling and use within Pakistan. ANF works under the umbrella of Pakistan Army and Ministry of Narcotics Control (Pakistan) of which Ijaz Ahmed Shah is the minister since December 2020. Due to misconception on Section 4 of ANF ACT 1997, the force's head consisted of the active-duty general officer of Pakistan Army. Although the law prescribes that any competent person may be appointed as Director-General. Currently, a two-star Army Officer, Major general Arif Malik HI(M) is deputed as Director-General. The ANF also has sole responsibility for coordinating and pursuing Pakistan narcotics investigations abroad.

Tobacco harm reduction (THR) is a public health strategy to lower the health risks to individuals and wider society associated with using tobacco products. It is an example of the concept of harm reduction, a strategy for dealing with the use of drugs. Tobacco smoking is widely acknowledged as a leading cause of illness and death, and reducing smoking is vital to public health.

A drug policy is the policy, usually of a government, regarding the control and regulation of psychoactive substances, particularly those that are addictive or cause physical and mental dependence. Governments try to combat drug addiction or dependence with policies that address both the demand and supply of drugs, as well as policies that mitigate the harms of drug use, and for medical treatment. Demand reduction measures include voluntary treatment, rehabilitation, substitution therapy, overdose management, alternatives to incarceration for drug related minor offenses, medical prescription of drugs, awareness campaigns, community social services, and support for families. Supply side reduction involves measures such as enacting foreign policy aimed at eradicating the international cultivation of plants used to make drugs and interception of drug trafficking, fines for drug offenses, incarceration for persons convicted for drug offenses. Policies that help mitigate drug use include needle syringe programs and drug substitution programs, and free facilities for testing a drug's purity.

Drug liberalization is the process of decriminalizing or legalizing the use or sale of drugs. Variations of drug liberalization include: drug legalization, drug relegalization and drug decriminalization.

Illicit drug use in Australia is the recreational use of prohibited drugs in Australia. Illicit drugs include illegal drugs, pharmaceutical drugs when used for non-medical purposes, and other substances used inappropriately. According to government and community organisations, the use and abuse, and the illegality, of illicit drugs is a social, health and legal issue that creates an annual illegal market estimated to be worth A$6.7 billion.

Health in Bhutan is one of the government's highest priorities in its scheme of development and modernization. Health and related issues are overseen by the Ministry of Health, itself represented on the executive Lhengye Zhungtshog (cabinet) by the Minister of Health. As a component of Gross National Happiness, affordable and accessible health care is central to the public policy of Bhutan.

Ministry of National Health Services, Regulation and Coordination

The Ministry of National Health Services, Regulation and Coordination is a cabinet level ministry of the Government of Pakistan with responsibility for national public health.

K. Srinath Reddy

K. Srinath Reddy is the president of the Public Health Foundation of India and formerly headed the Department of Cardiology at All India Institute of Medical Sciences (AIIMS).

The Global Commission on Drug Policy (GCDP) is a panel of world leaders and intellectuals, with a Secretariat based in Geneva, Switzerland.

Ann McNeill British academic/tobacco policy expert

Professor Ann McNeill is a British academic and tobacco policy expert. She is currently a Professor of Tobacco Addiction in the National Addictions Centre at the King's College London Institute of Psychiatry and Deputy Director of the UK Centre for Tobacco Control Studies.

The scientific community in United States and Europe are primarily concerned with the possible effect of electronic cigarette use on public health. There is concern among public health experts that e-cigarettes could renormalize smoking, weaken measures to control tobacco, and serve as a gateway for smoking among youth. The public health community is divided over whether to support e-cigarettes, because their safety and efficacy for quitting smoking is unclear. Many in the public health community acknowledge the potential for their quitting smoking and decreasing harm benefits, but there remains a concern over their long-term safety and potential for a new era of users to get addicted to nicotine and then tobacco. There is concern among tobacco control academics and advocates that prevalent universal vaping "will bring its own distinct but as yet unknown health risks in the same way tobacco smoking did, as a result of chronic exposure", among other things.

Gerry Stimson is a British public health social scientist, emeritus professor at Imperial College London from 2004, and an honorary professor at the London School of Hygiene and Tropical Medicine from 2017. Stimson has over 220 scientific publications mainly on social and health aspects of illicit drug use, including HIV infection. He has sat on numerous editorial boards including AIDS, Addiction, and European Addiction Research, and with Tim Rhodes he was the co-editor-in-chief of the International Journal of Drug Policy from 2000 to 2016. He is one of the global leaders for research on and later advocacy for harm reduction.

FAAAT think & do tank

For Alternative Approaches to Addiction, Think & do tank (FAAAT), often shortened to FAAAT think & do tank, is an international non-profit organization created in 2015 and registered in France, with office in Paris (France). In May 2019 the organization started the process towards the discontinuation of its activities on 31 December 2019.

Emily Banks Epidemiologist and public health researcher

Emily Banks is a Professor of Epidemiology and Public Health at the Australian National University. She is also a visiting professor at The University of Oxford. Banks was influential in the establishment of three large-scale long-term cohort studies in two countries: the Million Women Study in the UK, UK Biobank and the 45 and Up Study in Australia. Several of her papers have been highly influential in national and international public health policy and practice. The 2003 Million Women Study paper on hormone replacement therapy (HRT) and breast cancer was the most frequently cited paper on breast cancer worldwide in 2003–2005 and led to immediate changes in HRT prescribing policy and practice. She led the scientific elements of the 2006 World Health Organization paper on female genital mutilation (FGM) and obstetric outcome, which influenced the UN resolution on the elimination of FGM. Her 2015 paper on smoking and mortality has been used to support Australian tobacco control legislation.

References

  1. "Une fondation suisse au secours (Financier) de l'OMS". Le Temps. 28 May 2020.
  2. http://www.bilanz.ch/luxus/geballte-macht Die Mächtigsten: Geballte Macht
  3. "Nicole Pepper for the Harm Reduction Coalition. Syringe Exchange in Prisons: The International Experience". Harm Reduction Coalition. 2007. Retrieved 31 Jul 2013.
  4. "Report of the International Narcotics Control Board for 1995" (PDF). International Narcotics Control Board. 1996. Retrieved 31 Jul 2013.
  5. Savary JF, Hallam C, Bewley-Taylor D (2009). "The Swiss Four Pillars Policy: an evolution from local experimentation to federal law" (PDF). The Beckley Foundation Drug Policy Programme. Briefing Paper Eighteen.
  6. Zeltner T, Kessler DA, Martiny A, Randera F (Jul 2000). "Tobacco Company Strategies to Undermine Tobacco Control Activities at the World Health Organization. Report of the Committee of Experts on Tobacco Industry Documents" (PDF). Geneva, Switzerland. Retrieved 2 August 2013.
  7. Reynolds LA, Tansey EM, eds. (2010) The transcript of a Witness Seminar organized by the Wellcome Trust Centre for the History of Medicine at UCL, in collaboration with the Department of Knowledge Management and Sharing, WHO, held in Geneva, on 26 February 2010. WHO Framework Convention on Tobacco Control. Retrieved 31 Jul 2013.
  8. Ullekh NP (Jun 2, 2013). "Tobacco industry's bet on India & China may lead to surge in lifestyle diseases: Thomas Zeltner". The Economic Times (India).
  9. "Swiss Federal Statistical Office: Costs, financing". Swiss Federal Administration. 2013. Retrieved 1 August 2013.
  10. "Trend zu mehr Eigenverantwortung und weniger Solidarität". Interpharma. 2013. Retrieved 1 August 2013.
  11. Cheng T-M (2010). "Understanding the 'Swiss watch' function of Switzerland's health system". Health Aff (Millwood). 29 (8): 1442–51. doi: 10.1377/hlthaff.2010.0698 . PMID   20707011.
  12. Cassels A. (Apr 2013). "Change @ WHO: New approach to financing". World Health Organization. Retrieved 1 August 2013.
  13. "WHO needs change". Nature Publishing Group. 12 May 2011. Retrieved 30 July 2013.
  14. "WHO reform process: Landmark events of the WHO reform process from the initial consultation on the future of financing for WHO". World Health Organization. Retrieved 30 July 2013.
  15. "WHO Foundation Established to Support Critical Global Health Needs". World Health Organization (see also: "WHO dot int", and "whofoundationproject dot org" ). May 27, 2020. Archived from the original on May 27, 2020. Retrieved May 27, 2020. Founding Board Members are: Mr. Bob Carter, Ms. Clare Akamanzi and Professor Thomas Zeltner.
  16. "Une fondation suisse au secours (Financier) de l'OMS". Le Temps. 28 May 2020.
  17. "WHO launches fundraising foundation in Geneva".
  18. "Die KPT ist erneut Spitze im Service" (in German). Konsumenteninfo AG. 19 Sep 2012. Retrieved 1 August 2013.